---
document_datetime: 2025-12-02 05:27:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/talmanco.html
document_name: talmanco.html
version: success
processing_time: 0.1223675
conversion_datetime: 2025-12-27 16:32:17.351541
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Talmanco (previously Tadalafil Generics)

[RSS](/en/individual-human-medicine.xml/65665)

##### Authorised

This medicine is authorised for use in the European Union

tadalafil Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Talmanco (previously Tadalafil Generics)](#news-on)
- [More information on Talmanco (previously Tadalafil Generics)](#more-information-on-talmanco-previously-tadalafil-generics-1043)
- [Related information](#related-information-495)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Talmanco. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Talmanco.

For practical information about using Talmanco, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Talmanco and what is it used for?

Talmanco is a medicine used to treat adults with pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity). PAH is abnormally high blood pressure in the arteries of the lungs. Talmanco is used in patients with class-II (slight limitation of physical activity) or class-III (marked limitation of physical activity) PAH.

Talmanco contains the active substance tadalafil.

Talmanco is a 'generic medicine'. This means that Talmanco contains the same active substance and works in the same way as a 'reference medicine' already authorised in the European Union (EU) called Adcirca.

## How is Talmanco used?

Talmanco can only be obtained with a prescription and treatment should be started and monitored by a doctor who has experience in the treatment of PAH.

Talmanco is available as 20 mg tablets. The recommended dose is two tablets (40 mg) once a day. Patients with mild or moderate kidney or liver problems should be started on a lower dose. Talmanco is not recommended for patients with severe kidney or liver problems.

## How does Talmanco work?

PAH is a debilitating disease where there is severe narrowing of the blood vessels of the lungs. This leads to high blood pressure in the vessels taking blood from the heart to the lungs and reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult. The active substance in Talmanco, tadalafil, belongs to a group of medicines called 'phosphodiesterase type 5 (PDE5) inhibitors', which means that it blocks the PDE5 enzyme. This enzyme is found in the blood vessels of the lungs. When the enzyme is blocked, a substance called 'cyclic guanosine monophosphate' (cGMP) cannot be broken down and remains in the vessels where it causes widening of the blood vessels. In patients with PAH, this lowers the blood pressure in the lungs and improves symptoms.

## How has Talmanco been studied?

Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Adcirca, and do not need to be repeated for Talmanco.

As for every medicine, the company provided studies on the quality of Talmanco. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Talmanco?

Because Talmanco is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Talmanco approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Talmanco has been shown to have comparable quality and to be bioequivalent to Adcirca. Therefore, the CHMP's view was that, as for Adcirca, the benefit outweighs the identified risk. The Committee recommended that Talmanco be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Talmanco?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Talmanco have been included in the summary of product characteristics and the package leaflet.

## Other information about Talmanco

The European Commission granted a marketing authorisation valid throughout the European Union for Tadalafil Generics on 9 January 2017. The name of the medicine was changed to Talmanco on 1 March 2017.

For more information about treatment with Talmanco, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Talmanco: EPAR - Summary for the public

Reference Number: EMA/33052/2017

English (EN) (93.25 KB - PDF)

**First published:** 26/01/2017

**Last updated:** 13/06/2017

[View](/en/documents/overview/talmanco-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-697)

български (BG) (120.55 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/bg/documents/overview/talmanco-epar-summary-public_bg.pdf)

español (ES) (92.96 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/es/documents/overview/talmanco-epar-summary-public_es.pdf)

čeština (CS) (117.9 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/cs/documents/overview/talmanco-epar-summary-public_cs.pdf)

dansk (DA) (92.47 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/da/documents/overview/talmanco-epar-summary-public_da.pdf)

Deutsch (DE) (94.09 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/de/documents/overview/talmanco-epar-summary-public_de.pdf)

eesti keel (ET) (91.81 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/et/documents/overview/talmanco-epar-summary-public_et.pdf)

ελληνικά (EL) (121.56 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/el/documents/overview/talmanco-epar-summary-public_el.pdf)

français (FR) (93.31 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/fr/documents/overview/talmanco-epar-summary-public_fr.pdf)

hrvatski (HR) (112.36 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/hr/documents/overview/talmanco-epar-summary-public_hr.pdf)

italiano (IT) (92.14 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/it/documents/overview/talmanco-epar-summary-public_it.pdf)

latviešu valoda (LV) (114.82 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/lv/documents/overview/talmanco-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (115.4 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/lt/documents/overview/talmanco-epar-summary-public_lt.pdf)

magyar (HU) (112.54 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/hu/documents/overview/talmanco-epar-summary-public_hu.pdf)

Malti (MT) (117.86 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/mt/documents/overview/talmanco-epar-summary-public_mt.pdf)

Nederlands (NL) (92.87 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/nl/documents/overview/talmanco-epar-summary-public_nl.pdf)

polski (PL) (117.92 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/pl/documents/overview/talmanco-epar-summary-public_pl.pdf)

português (PT) (93.05 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/pt/documents/overview/talmanco-epar-summary-public_pt.pdf)

română (RO) (112.91 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/ro/documents/overview/talmanco-epar-summary-public_ro.pdf)

slovenčina (SK) (117.22 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/sk/documents/overview/talmanco-epar-summary-public_sk.pdf)

slovenščina (SL) (111.77 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/sl/documents/overview/talmanco-epar-summary-public_sl.pdf)

Suomi (FI) (91.94 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/fi/documents/overview/talmanco-epar-summary-public_fi.pdf)

svenska (SV) (92.44 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/sv/documents/overview/talmanco-epar-summary-public_sv.pdf)

## Product information

Talmanco : EPAR - Product Information

English (EN) (673.64 KB - PDF)

**First published:** 26/01/2017

**Last updated:** 09/04/2025

[View](/en/documents/product-information/talmanco-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-301)

български (BG) (560.21 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/bg/documents/product-information/talmanco-epar-product-information_bg.pdf)

español (ES) (299.99 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/es/documents/product-information/talmanco-epar-product-information_es.pdf)

čeština (CS) (332.31 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/cs/documents/product-information/talmanco-epar-product-information_cs.pdf)

dansk (DA) (271.21 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/da/documents/product-information/talmanco-epar-product-information_da.pdf)

Deutsch (DE) (317.57 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/de/documents/product-information/talmanco-epar-product-information_de.pdf)

eesti keel (ET) (359.35 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/et/documents/product-information/talmanco-epar-product-information_et.pdf)

ελληνικά (EL) (384.47 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/el/documents/product-information/talmanco-epar-product-information_el.pdf)

français (FR) (356.3 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/fr/documents/product-information/talmanco-epar-product-information_fr.pdf)

hrvatski (HR) (330.16 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/hr/documents/product-information/talmanco-epar-product-information_hr.pdf)

íslenska (IS) (414.75 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/is/documents/product-information/talmanco-epar-product-information_is.pdf)

italiano (IT) (338.56 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/it/documents/product-information/talmanco-epar-product-information_it.pdf)

latviešu valoda (LV) (338.94 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/lv/documents/product-information/talmanco-epar-product-information_lv.pdf)

lietuvių kalba (LT) (324.09 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/lt/documents/product-information/talmanco-epar-product-information_lt.pdf)

magyar (HU) (343.72 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/hu/documents/product-information/talmanco-epar-product-information_hu.pdf)

Malti (MT) (322.66 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/mt/documents/product-information/talmanco-epar-product-information_mt.pdf)

Nederlands (NL) (282.55 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/nl/documents/product-information/talmanco-epar-product-information_nl.pdf)

norsk (NO) (323.73 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/no/documents/product-information/talmanco-epar-product-information_no.pdf)

polski (PL) (343.24 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/pl/documents/product-information/talmanco-epar-product-information_pl.pdf)

português (PT) (283.42 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/pt/documents/product-information/talmanco-epar-product-information_pt.pdf)

română (RO) (335.39 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/ro/documents/product-information/talmanco-epar-product-information_ro.pdf)

slovenčina (SK) (327.45 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/sk/documents/product-information/talmanco-epar-product-information_sk.pdf)

slovenščina (SL) (332.62 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/sl/documents/product-information/talmanco-epar-product-information_sl.pdf)

Suomi (FI) (281.42 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/fi/documents/product-information/talmanco-epar-product-information_fi.pdf)

svenska (SV) (239.11 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

09/04/2025

[View](/sv/documents/product-information/talmanco-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000177149 26/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Talmanco: EPAR - All Authorised presentations

English (EN) (33.18 KB - PDF)

**First published:** 26/01/2017

**Last updated:** 13/06/2017

[View](/en/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-748)

български (BG) (35.49 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/bg/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_bg.pdf)

español (ES) (32.69 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/es/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_es.pdf)

čeština (CS) (34.09 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/cs/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (33.24 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/da/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (34.34 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/de/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (33.35 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/et/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (36.65 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/el/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_el.pdf)

français (FR) (32.98 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/fr/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (33.17 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/hr/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (27.28 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/is/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_is.pdf)

italiano (IT) (26.53 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/it/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.29 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/lv/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.84 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/lt/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (34 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/hu/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.26 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/mt/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (32.95 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/nl/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (33.58 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/no/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_no.pdf)

polski (PL) (34.57 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/pl/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_pl.pdf)

português (PT) (33.03 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/pt/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.06 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/ro/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (34.38 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/sk/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (32.93 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/sl/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (32.74 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/fi/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (32.69 KB - PDF)

**First published:**

26/01/2017

**Last updated:**

13/06/2017

[View](/sv/documents/all-authorised-presentations/talmanco-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Talmanco (previously Tadalafil Generics) Active substance tadalafil International non-proprietary name (INN) or common name tadalafil Therapeutic area (MeSH) Hypertension, Pulmonary Anatomical therapeutic chemical (ATC) code G04BE08

### Pharmacotherapeutic group

Urologicals

### Therapeutic indication

Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.

## Authorisation details

EMA product number EMEA/H/C/004297

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Dublin 15 Ireland

Opinion adopted 10/11/2016 Marketing authorisation issued 09/01/2017 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Talmanco: EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.1 KB - PDF)

**First published:** 09/04/2025

[View](/en/documents/procedural-steps-after/talmanco-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Talmanco: EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (120.28 KB - PDF)

**First published:** 13/06/2017

**Last updated:** 09/11/2023

[View](/en/documents/procedural-steps-after/talmanco-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Tadalafil Generics : EPAR - Public assessment report

Reference Number: EMA/803097/2016

English (EN) (288.48 KB - PDF)

**First published:** 26/01/2017

**Last updated:** 26/01/2017

[View](/en/documents/assessment-report/tadalafil-generics-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tadalafil Generics

Adopted

Reference Number: EMA/CHMP/697437/2016

English (EN) (75.19 KB - PDF)

**First published:** 11/11/2016

**Last updated:** 11/11/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tadalafil-generics_en.pdf)

#### News on Talmanco (previously Tadalafil Generics)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2016) 11/11/2016

#### More information on Talmanco (previously Tadalafil Generics)

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0042970000) (Initial marketing authorisation)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/04/2025

## Share this page

[Back to top](#main-content)